BiondVax is a publicly traded, innovative biopharmaceutical company developing a Universal Flu Vaccine, providing multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic.
| Website: | www.biondvax.com |
| Main Phone: | +972 89302529 |
| Address: | Hadassah Ein Kerem Campus |
| Address 2: | Jerusalem BioPark, 2nd floor |
| City / Town: | Jerusalem |
| Country: | ISR |
| Postal Code: | 74036 |
| Exchange: | NSC |
| CEO: | Ron Babecoff |
| Employees: | 21 |
Gathering Data... Please wait
BiondVax is a publicly traded, innovative biopharmaceutical company developing a Universal Flu Vaccine, providing multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic.
| Website: | www.biondvax.com |
| Main Phone: | +972 89302529 |
| Address: | Hadassah Ein Kerem Campus |
| Address 2: | Jerusalem BioPark, 2nd floor |
| City / Town: | Jerusalem |
| Country: | ISR |
| Postal Code: | 74036 |
| Exchange: | NSC |
| CEO: | Ron Babecoff |
| Employees: | 21 |
| Last Price 5.75 | Change $ -0.2 | Change % -3.36 | Tick N/A |
| Bid N/A | Bid Size 0.00 | Ask 7.40 | Ask Size 900.00 |
| Open 5.98 | High 6.00 | Low 5.75 | Prev Close 5.95 |
| Last Trade | Volume 6,028 | 52 Wk Hi 7.26 | 52 Wk Low 3.51 |
| Market Cap 37.6 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 6,535,489.00 | EPS (TTM) -3.06 | PE Ratio N/A | Exchange NCM |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 37 | 30 | 30 | 37 |
| Low Target Price Estimate | 37 | 30 | 30 | 37 |
| Mean Target Price Estimate | 37 | 30 | 30 | 37 |
| Standard Deviation | 0 | 0 | 0 | 0 |
| Date of Most Recent Estimate | 06/01/18 | 05/07/18 | 05/07/18 | 06/01/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 15 | 2018-05-29 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 7 | 2018-05-01 |
| 20-F | Annual and transition report of foreign private issuers under sections 13 or 15(d) | 232 | 2018-04-30 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 5 | 2018-04-18 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 3 | 2018-03-29 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 3 | 2018-03-21 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 4 | 2018-03-14 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 32 | 2018-02-22 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 3 | 2018-02-22 |
| SC 13G/A | Amendment to the SC 13G filing | 9 | 2018-02-02 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 1 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 0 | 0 | 0 | 1 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
